Status:
UNKNOWN
International Clinical Study of Zhizhu Kuanzhong Capsule
Lead Sponsor:
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Conditions:
Functional Dyspepsia
Postprandial Distress Syndrome
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
This trial aims to evaluate the clinical efficacy and safety of Zhizhu Kuanzhong Capsule in the treating patients with functional dyspepsia postprandial distress syndrome(FD PDS). Half of participants...
Detailed Description
Functional dyspepsia (FD) is one of the most common functional gastrointestinal disorders. Current data from clinical studies have shown that traditional Chinese medicine can obviously relieve clinica...
Eligibility Criteria
Inclusion
- Meeting the Rome IV diagnostic criteria for functional dyspepsia-postprandial distress syndrome;
- \* At least 3 days during the one-week run-in period with VAS score ≥ 4 for major symptoms (at least one of postprandial fullness discomfort and early satiety) .
- Age between 18 and 65 years old (including 18 and 65 years old), male or female, outpatients;
- \*\*Be able to discontinue prohibited medications that may affect the evaluation of the effectiveness, such as acid inhibition/antacids, prokinetic agents, non-steroidal anti-inflammatory drugs, anticholinergic agents, glucocorticoids, and therapeutic medication for H. pylori eradication.
- Each subject is informed and voluntarily signed the informed consent form(ICF).
- Subjects who entered the one-week run-in period are self-rated on the Visual Analogue Score (VAS) for the degree of discomfort with both symptoms of postprandial fullness and early fullness, with subjects indicating the degree of discomfort on a 10 cm ruler marked 0- "Asymptomatic or No Discomfort"and 10- "Extreme Severe or Extreme Discomfort"at its head and tail, respectively. The rating was made once a day and 7 days a week with scores of 0 to 10.
- A 2-week wash-out period is required for patients taking prohibited medications prior to screening.
Exclusion
- Gastroscopic findings of gastric cancer, peptic ulcer, erosive gastritis (grade 2 or higher), moderate to severe atrophic gastritis, dysplasia, or other organ gastrointestinal disease.
- Patients with a history of abdominal surgery (except for appendectomy and cesarean section).
- Patients with immune system defects (such as leukaemia or cancer), or those who have been administered immunosuppressive agents or glucocorticoids within the past 3 months.
- Patients who combined severe cardiac and pulmonary insufficiency, insufficiency of liver (ALT/AST \> 1.5 times the upper limit of the normal value) and kidney insufficiency (BUN/Serum Creatinine \> the upper limit of the normal value), abnormal of endocrine system( such as diabetes and thyroid dysfunction), abnormal hematopoietic system, and iron deficiency anemia as indicated on hematological examination.
- Patients with severe anxiety and depression.
- Patients with psychosis and mental retardation as well as language disorder precluding the ability of filling scales or recording symptoms.
- Pregnant (a female of childbearing potential with a positive pregnancy test) or lactating females; or patients of childbearing potential without effective contraception.
- Patients who are known to be allergic to the ingredients of this drug.
- Patients who are suspected to have or indeed have a history of alcohol or drug abuse.
- Patients who have participated in a clinical trial in the past 3 months.
- Patients who are deemed by the investigator as being not suitable for participation in the clinical trial.
Key Trial Info
Start Date :
October 24 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
480 Patients enrolled
Trial Details
Trial ID
NCT03825692
Start Date
October 24 2019
End Date
December 1 2023
Last Update
August 4 2023
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Alexandra Hospital
Brisbane, Queensland, Australia
2
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Beijing, Beijing Municipality, China, 100091
3
Beijing Jishuitan Hospital
Beijing, Beijing Municipality, China
4
Peking Union Medical College Hospital of Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China